Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 5:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 105 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Estradiol 2 Mg tablet Clear all
Completed Phase 1 Interventional Results available

This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer

NCT03099174
View directory record Official record
Conditions
Neoplasms, Breast Neoplasms
Interventions
Xentuzumab, Abemaciclib, Letrozole, Anastrozole, Fulvestrant
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
6
States / cities
Santa Monica, California • New Haven, Connecticut • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2025 · Synced Sep 20, 2026, 5:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluate the Effect of Ethinyl Estradiol/Norgestimate on the Pharmacokinetics of Lomitapide in Healthy Female Subjects

NCT02080468
View directory record Official record
Conditions
Healthy
Interventions
lomitapide, EE/norgestimate
Drug
Lead sponsor
Aegerion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2019 · Synced Sep 20, 2026, 5:46 AM EDT
Terminated Phase 2 Interventional Results available

A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy

NCT03584009
View directory record Official record
Conditions
Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer
Interventions
Venetoclax, Fulvestrant
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
21
States / cities
Phoenix, Arizona • Springdale, Arkansas • La Jolla, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2022 · Synced Sep 20, 2026, 5:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Atazanavir and Ritonavir (ATV/RTV) and an Oral Contraceptive in Healthy Females

NCT00357604
View directory record Official record
Conditions
HIV Infections
Interventions
Ortho Tri-Cyclen (ethinyl estradiol + norgestimate), Ortho Tri-Cyclen LO (ethinyl estradiol + norgestimate) + Atazanavir/Ritonavir for 14 days then Ortho Tri-Cyclen for 7 days
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2011 · Synced Sep 20, 2026, 5:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Erenumab (AMG 334) Plus Combined Oral Contraceptive Drug Interaction Study in Healthy Females

NCT02792517
View directory record Official record
Conditions
Headache, Migraine
Interventions
Erenumab, Ethynil Estradiol/Norgestimate Oral Contraceptive
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
4
States / cities
Anaheim, California • Cypress, California • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Sep 20, 2026, 5:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Impact of Estrogen on Fear Extinction R61

NCT02673606
View directory record Official record
Conditions
Fear, Fear; Examination, Phobic
Interventions
Estradiol 2Mg Tablet, Estradiol 4Mg Tablet, Placebo Pills
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 29, 2020 · Synced Sep 20, 2026, 5:46 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Oral Versus Patch Hormonal Contraceptive Effects on Metabolism, Clotting, Inflammatory Factors and Vascular Reactivity

NCT00439972
View directory record Official record
Conditions
Contraception
Interventions
Ortho-Cyclen (R), Ortho Evra (R), extended use of Ortho Evra (R)
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 13, 2011 · Synced Sep 20, 2026, 5:46 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

NCT04305496
View directory record Official record
Conditions
Locally Advanced (Inoperable) or Metastatic Breast Cancer
Interventions
Fulvestrant, Capivasertib, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
818 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
22
States / cities
Gilbert, Arizona • Orange, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 20, 2026, 5:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects

NCT03662516
View directory record Official record
Conditions
Healthy Females
Interventions
PF-04965842, Ethinyl estradiol (EE) and levonorgestrel (LN)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 22, 2020 · Synced Sep 20, 2026, 5:46 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy and Safety of Two Flexible Extended Regimens of BAY86-5300 (SH T00186D) in Comparison With the Conventional Regimen of YAZ

NCT00567164
View directory record Official record
Conditions
Contraception, Ovulation Inhibition, Contraceptives, Oral
Interventions
EE20/DRSP (BAY86-5300), EE20/DRSP (YAZ, BAY86-5300)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
1,887 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
85
States / cities
Montgomery, Alabama • Chandler, Arizona • Mesa, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2014 · Synced Sep 20, 2026, 5:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug Interaction Study of Danicopan

NCT04709094
View directory record Official record
Conditions
Healthy
Interventions
Danicopan, Warfarin, Bupropion, Ethinyl Estradiol/Norethindrone
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 13, 2021 · Synced Sep 20, 2026, 5:46 AM EDT
Completed Phase 2 Interventional

A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants

NCT05963984
View directory record Official record
Conditions
Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer
Interventions
Samuraciclib, Fulvestrant
Drug
Lead sponsor
Carrick Therapeutics Limited
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
5
States / cities
Ocala, Florida • Baltimore, Maryland • Kansas City, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2025 · Synced Sep 20, 2026, 5:46 AM EDT
Recruiting Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

NCT05646862
View directory record Official record
Conditions
Breast Cancer
Interventions
Inavolisib, Fulvestrant, Alpelisib, Bupropion, Omeprazole, Midazolam
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
39
States / cities
Greenbrae, California • Los Alamitos, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 20, 2026, 5:46 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer

NCT04214288
View directory record Official record
Conditions
Advanced ER-Positive HER2-Negative Breast Cancer
Interventions
AZD9833, Fulvestrant
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
9
States / cities
Birmingham, Alabama • Long Beach, California • Fort Myers, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 20, 2026, 5:46 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy of Seasonique for the Treatment of Cyclic Pelvic Pain

NCT00196365
View directory record Official record
Conditions
Dysmenorrhea
Interventions
levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets, levonorgestrel/EE 0.15/0.03 mg tablets and placebo
Drug
Lead sponsor
Duramed Research
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
18
States / cities
Huntsville, Alabama • Phoenix, Arizona • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 11, 2014 · Synced Sep 20, 2026, 5:46 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Evaluate Safety and Efficacy of an OC Preparation vs Placebo for 6 Treatment Cycles in Women With Moderate Acne.

NCT00651469
View directory record Official record
Conditions
Acne Vulgaris
Interventions
YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
14 Years to 45 Years · Female only
Enrollment
534 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
27
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2014 · Synced Sep 20, 2026, 5:46 AM EDT
Completed Phase 2 Interventional

ER Reactivation Therapy for Breast Cancer

NCT02188745
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
17B-estradiol, Letrozole, Anastrozole, Exemestane
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
3
States / cities
Springfield, Massachusetts • Rochester, Minnesota • Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Sep 20, 2026, 5:46 AM EDT
Terminated Phase 2 Interventional Results available

Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer

NCT03289039
View directory record Official record
Conditions
Breast Cancer
Interventions
Neratinib, Fulvestrant
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
6
States / cities
Indianapolis, Indiana • Brewer, Maine • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 20, 2026, 5:46 AM EDT
Completed Phase 2 Interventional Results available

Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor

NCT00754325
View directory record Official record
Conditions
Advanced Breast Cancer
Interventions
Dasatinib, Fulvestrant
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
28
States / cities
Sedona, Arizona • Tucson, Arizona • Hudson, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated May 25, 2016 · Synced Sep 20, 2026, 5:46 AM EDT
Completed Phase 2 Interventional Results available

Study of Combined Fulvestrant and Everolimus in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure

NCT00570921
View directory record Official record
Conditions
Breast Cancer
Interventions
Everolimus, Fulvestrant
Drug
Lead sponsor
Mara Chambers
Other
Eligibility
45 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Sep 20, 2026, 5:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Effect of Tirzepatide on How the Body Handles Birth Control Pills in Healthy Female Participants

NCT04172987
View directory record Official record
Conditions
Healthy
Interventions
Tirzepatide, EE/NGM
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 26, 2023 · Synced Sep 20, 2026, 5:46 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Study in Women on the Effect of JNJ-64530440 on Oral Contraceptive and Midazolam, and the Effect of a High-fat Meal on JNJ-64530440

NCT03890341
View directory record Official record
Conditions
Healthy
Interventions
Drospirenone/Ethinylestradiol, Midazolam, JNJ-64530440
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Sep 20, 2026, 5:46 AM EDT
Recruiting Phase 4 Interventional

Modifying Progesterone and Estradiol Levels to Prevent Postpartum Cigarette Smoking Relapse and Reduce Secondhand Smoke Exposure in Infants and Children

NCT04783857
View directory record Official record
Conditions
Smoking, Smoking Cessation, Smoking Reduction
Interventions
Progesterone 200 MG Oral Capsule
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 20, 2026, 5:46 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

NCT03424005
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Capecitabine, Atezolizumab, Ipatasertib, SGN-LIV1A, Bevacizumab, Chemotherapy (Gemcitabine + Carboplatin or Eribulin), Selicrelumab, Tocilizumab, Nab-Paclitaxel, Sacituzumab Govitecan, Abemaciclib, Fulvestrant, Ribociclib (Dose #1), Inavolisib (Dose #1), Trastuzumab Deruxtecan, Ribociclib (Dose #2), Letrozole, Inavolisib (Dose #2), Empagliflozin, Palbociclib, Metformin, Atirmociclib, Giredestrant
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
24
States / cities
Duarte, California • Irvine, California • La Jolla, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 20, 2026, 5:46 AM EDT